long intergenic non-protein coding RNA 2382Genealiases: []
Q-omics provides the consensus-scored LINC02382 profile across patient tissues and cancer cell-line models. LINC02382 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, LINC02382 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, LINC02382 RNA expression shows 6,363 significant gene co-expression associations, with the highest sampling consensus in HNSC. Together, these results highlight ESCA, BRCA, and HNSC as cancer lineages where LINC02382 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02382 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02382 survival associations across molecular data types. LINC02382 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02382 RNA expression–survival associations across cancer types. High LINC02382 expression shows unfavorable associations in ESCA, LIHC, KIRP, DLBC, COAD and STAD. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify ESCA as the clearest survival context for LINC02382 RNA expression.
This table summarizes LINC02382 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02382. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02382 shows lower tumor expression in BRCA and LUAD and higher tumor expression in HNSC and LUSC. The BRCA box plot shows higher LINC02382 RNA expression in normal versus tumor tissue (log2 FC = −0.228, t-test p < 0.001).
This table shows molecular features associated with LINC02382 in patient tissues and cancer cell lines. In patient samples, LINC02382 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
